Our Offerings
By Industry By Function
About Us
Our Viewpoint
NEW
 Senior Management Experts Panel Global Consultants Press Releases Blog
Infographics Market Insights Case Studies Illustrations In The Press
Contact Us
The Business Research Company Logo
Reports Store
Top 50 Healthcare Market Reports
NEW
 Top 50 Non-Healthcare Market Reports
NEW
 Opportunities And Strategies Reports Aerospace And Defense Agriculture Chemicals Construction
Electrical And Electronics Financial Services Food And Beverages Healthcare Services Hospitality Information Technology Machinery Media
Medical Equipment Metal And Mineral Mining Oil And Gas Paper, Plastics, Rubber, Wood And Textile Pharmaceuticals Professional Services Recreation
Retail And Wholesale Services Social Services Transport Transport Services Utilities Veterinary Healthcare Filter Reports by Trends
NEW
Market Intelligence Platform
About GMM Global Forecast
NEW
 Mega Trends Analysis
Consultancies Corporate Planning & Strategy Academic Financial Services Legal Services
Pricing Methodology Sources FAQ Press Coverage
Customized Research
Find Customers Optimise Your Marketing Mix Evaluate Competitors Identify Market Opportunities Develop Products And Services
Distributor And Partner Research Plan Finances Streamline Your Operations Devise Market Entry Strategy Explore Custom Research Packages
NEW
Continuous Research
Desk Research Research Reports Senior Executive Interviews Consumer Research Market Sizing And Forecasts
Company Information Analytics And Data Visualization Research Automation Web Crawling And Spidering AI-Empowered Research Services
Request Proposal
Drugs For Benign Prostatic hypertrophy Global Market Report 2025
Request Sample Buy Now
Global Drugs For Benign Prostatic hypertrophy Market Report 2025

Report Price : $4490.00

Pages : 175

Format : PDF

Published : January 2025

Delivery Time : 2-3 Business Days

Purchase This Report
Purchase This Report

Drugs For Benign Prostatic hypertrophy Global Market Report 2025

By Type (Alpha Blocker, 5-alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitor, Other Types), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End User (Hospital Pharmacies, Retail Pharmacies, Other End-Users) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Drugs For Benign Prostatic hypertrophy Market Overview

• Drugs For Benign Prostatic hypertrophy market size has reached to $4.31 billion in 2024

• Expected to grow to $5.52 billion in 2029 at a compound annual growth rate (CAGR) of 5%

• Growth Driver: Rising Geriatric Population Drives Growth Of Benign Prostatic Hypertrophy Drugs Market

• Market Trend: Innovations In Benign Prostatic Hypertrophy Treatment

• North America was the largest region in 2024 and Middle East is the fastest growing region.

What Is Covered Under Drugs For Benign Prostatic hypertrophy Market?

The drug benign prostatic hypertrophy refers to benign prostatic hypertrophy drugs that are used to treat enlarged prostate glands by relaxing bladder neck muscles and muscle fibers in the prostate, making urination easier. Benign Prostatic Hypertrophy is commonly seen in men older than 50.

The main types of drugs for benign prostatic hypertrophy are alpha-blockers, 5-alpha reductase inhibitors, phosphodiesterase-5 inhibitors, and others. Alpha-blockers, commonly known as blockers or adrenoreceptor antagonists, are a type of pharmaceutical drug that works by blocking adrenergic receptors. The different sectors include hospital pharmacies, retail pharmacies, and others and are distributed through various channels, such as hospital pharmacies, retail pharmacies, and online pharmacies.

Drugs For Benign Prostatic hypertrophy Market 2025 - 2034

What Is The Drugs For Benign Prostatic hypertrophy Market Size 2025 And Growth Rate?

The drugs for benign prostatic hypertrophy market size has grown strongly in recent years. It will grow from $4.31 billion in 2024 to $4.55 billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to aging population, increased awareness, advancements in drug therapies, healthcare access.

What Is The Drugs For Benign Prostatic hypertrophy Market Growth Forecast?

The drugs for benign prostatic hypertrophy market size is expected to see strong growth in the next few years. It will grow to $5.52 billion in 2029 at a compound annual growth rate (CAGR) of 5.0%. The growth in the forecast period can be attributed to emerging markets, new drug developments, increasing awareness and education, regulatory approvals. Major trends in the forecast period include minimally invasive treatments, personalized medicine, combination therapies, patient-centered care, telemedicine and digital health, research and development.

The forecast of 5.0% growth over the next five years remains unchanged from the previous projection for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper U.S. urology practices by increasing the cost of alpha-blocker medications imported from Canada and Ireland, thereby delaying BPH symptom relief and elevating men's health treatment expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

What’s The Trade War Impact On Pharmaceuticals Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

How Is The Drugs For Benign Prostatic hypertrophy Market Segmented?

1) By Type: Alpha Blocker, 5-alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitor, Other Types

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By End User: Hospital Pharmacies, Retail Pharmacies, Other End-Users

Subsegments:

1) By Alpha Blocker: Tamsulosin, Alfuzosin, Doxazosin, Terazosin, Silodosin

2) By 5-alpha Reductase Inhibitor: Finasteride, Dutasteride

3) By Phosphodiesterase-5 Inhibitor: Tadalafil, Sildenafil

4) By Other Types: Anticholinergics, Herbal Supplements (Saw Palmetto), Combination Therapy Drugs (Alpha Blocker + 5-alpha Reductase Inhibitor)

What Is Driving The Drugs For Benign Prostatic hypertrophy Market? Rising Geriatric Population Drives Growth Of Benign Prostatic Hypertrophy Drugs Market

The rising male geriatric population globally is driving the growth of drugs for benign prostatic hypertrophy market for Benign Prostatic Hypertrophy drugs as the condition is commonly seen in men aged over 50 years. For instance, in October 2022, according to the World Health Organization, a US-based specialized health agency, globally, 1 in 6 individuals would be 60 or older by 2030 and is expected to reach 2.1 billion elderly people by 2050. According to the National Institute of Health (NIH), Benign Prostatic Hyperplasia affects around 50% of men aged between 51 and 60 years and up to 90% of men aged over 80 years.

What Is Driving The Drugs For Benign Prostatic hypertrophy Market? Increasing Prostate Cancer Cases Accelerate Growth In Benign Prostatic Hypertrophy Drug Market

The increased prevalence of prostate diseases is expected to propel the growth of the drugs for benign prostatic hypertrophy market going forward. Prostate diseases refer to a group of medical conditions that affect the prostate gland, a male reproductive organ located just below the bladder. Drugs for benign prostatic hypertrophy (BPH) are important in managing and alleviating urinary symptoms associated with prostate diseases, providing relief by reducing prostate gland enlargement and improving urine flow. For instance, In June 2024, according to the Centers for Disease Control and Prevention, a US-based government agency In the United States, 236,659 new cases of prostate cancer were reported in 2021, and 33,363 men died from the disease in 2022. Therefore, the increased prevalence of prostate diseases is driving the growth of the drugs for benign prostatic hypertrophy industry.

Who Are The Major Players In The Global Drugs For Benign Prostatic hypertrophy Market?

Major companies operating in the drugs for benign prostatic hypertrophy market include Allergan Inc., Astellas Pharma Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Sanofi S.A., Nymox Pharmaceutical Corporation, Æterna Zentaris Inc., Pfizer Inc., IntelGenx Technologies Corp., Ipsen S.A., Novartis International AG, Antibe Therapeutics Inc., Bausch Health Companies Inc., Bayer AG, Quest PharmaTech Inc., Bristol-Myers Squibb Company, Endo Pharmaceuticals Inc., Kaken Pharmaceutical Co. Ltd., Impax Laboratories Inc., GemVax & KAEL Inc., Merck & Co. Inc., Kissei Pharmaceutical Co. Ltd., Abbott Laboratories, Allium Medical Solutions Ltd., Asahi Kasei Corporation, Asclepion Laser Technologies GmbH, Boston Scientific Corporation, Biolitec AG, Coloplast A/S, Eli Lilly and Company, Endo International plc, IPG Photonics Corporation, KARL STORZ SE & Co. KG, LISA Laser Products AG, Medifocus Inc., Olympus Corporation, Pharex Health Corporation, PNN Medical A/S, Quanta S.p.A.

What Are The Key Trends Of The Global Drugs For Benign Prostatic hypertrophy Market? Innovations In Benign Prostatic Hypertrophy Treatment

Major companies operating in the drugs for benign prostatic hypertrophy market are focusing on developing innovative products, such as Polish drugs, to effectively support patients with urological diseases. Polish drugs are pharmaceutical products used to diagnose, treat, prevent, or alleviate symptoms of diseases and conditions, regulated for safety, efficacy, and quality by relevant health authorities. For instance, in June 2023, Adamed Sp. z o.o., a Poland-based pharma company, launched a combination drug, solifenacin succinate + tamsulosin hydrochloride. These products are combined in a fixed-dose medication to effectively treat lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). This combination enhances the therapeutic benefits by reducing bladder contractions through solifenacin while facilitating urination via tamsulosin, leading to improved patient outcomes compared to tamsulosin monotherapy.

What Are The Key Trends Of The Global Drugs For Benign Prostatic hypertrophy Market? New Treatment Option For BPH And ED, Akums Drugs Unveils Cromax Capsule

Major companies operating in the drugs for benign prostatic hypertrophy market are focusing on developing solutions with technological advancement, such as new medication for both enlarged prostate (benign prostatic hyperplasia, BPH) and erectile dysfunction, to gain a competitive edge in the market. Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement of the prostate gland. And erectile dysfunction (ED) refers to the inability to achieve or maintain an erection sufficient for sexual activity. For instance, in September 2023, Akums Drugs and Pharmaceuticals Ltd., an Indian-based paint and coating manufacturing pharmaceutical contract manufacturer, launched Tamsulosin + Tadalafil Capsule to expand its product offerings in the pharmaceutical sector, particularly in areas that address common men's health issues. This innovative product, Cromax, offers unique features such as a dual-action formulation combining Tamsulosin, which targets smooth muscle relaxation in the prostate and urethra to improve urine flow, and Tadalafil, which enhances blood flow to the penis to facilitate erections. This combination therapy not only provides a more convenient treatment option for men suffering from both benign prostatic hyperplasia (BPH) and erectile dysfunction but also demonstrates significant improvements in the International Prostate Symptom Score (IPSS).

Need data on a specific region in this market?
Request Customisation

Regional Outlook For The Global Drugs For Benign Prostatic hypertrophy Market

North America was the largest region in the drugs for benign prostatic hypertrophy market in 2024. Middle East is expected to be the fastest-growing region in the drugs for benign prostatic hypertrophy market. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

What Defines the Drugs For Benign Prostatic hypertrophy Market?

The drugs for benign postratic hypertrophy market consists of sales of alfuzosin (Uroxatral), doxazosin (Cardura), tamsulosin (Flomax) and silodosin (Rapaflo). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Drugs For Benign Prostatic hypertrophy Industry?

The drugs for benign prostatic hypertrophy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the drugs for benign prostatic hypertrophy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Drugs For Benign Prostatic hypertrophy Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2025 $4.55 billion
Revenue Forecast In 2034 $5.52 billion
Growth Rate CAGR of 5% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Type: Alpha Blocker, 5-alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitor, Other Types
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By End User: Hospital Pharmacies, Retail Pharmacies, Other End-Users Subsegments: 1) By Alpha Blocker: Tamsulosin, Alfuzosin, Doxazosin, Terazosin, Silodosin
2) By 5-alpha Reductase Inhibitor: Finasteride, Dutasteride
3) By Phosphodiesterase-5 Inhibitor: Tadalafil, Sildenafil
4) By Other Types: Anticholinergics, Herbal Supplements (Saw Palmetto), Combination Therapy Drugs (Alpha Blocker + 5-alpha Reductase Inhibitor)
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Allergan Inc., Astellas Pharma Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Sanofi S.A., Nymox Pharmaceutical Corporation, Æterna Zentaris Inc., Pfizer Inc., IntelGenx Technologies Corp., Ipsen S.A., Novartis International AG, Antibe Therapeutics Inc., Bausch Health Companies Inc., Bayer AG, Quest PharmaTech Inc., Bristol-Myers Squibb Company, Endo Pharmaceuticals Inc., Kaken Pharmaceutical Co. Ltd., Impax Laboratories Inc., GemVax & KAEL Inc., Merck & Co. Inc., Kissei Pharmaceutical Co. Ltd., Abbott Laboratories, Allium Medical Solutions Ltd., Asahi Kasei Corporation, Asclepion Laser Technologies GmbH, Boston Scientific Corporation, Biolitec AG, Coloplast A/S, Eli Lilly and Company, Endo International plc, IPG Photonics Corporation, KARL STORZ SE & Co. KG, LISA Laser Products AG, Medifocus Inc., Olympus Corporation, Pharex Health Corporation, PNN Medical A/S, Quanta S.p.A.
Customization Scope Request for Sample
Pricing And Purchase Options Explore Purchase Options
Market Size Value In 2025 $4.55 billion
Revenue Forecast In 2034 $5.52 billion
Growth Rate CAGR of 5% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Type: Alpha Blocker, 5-alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitor, Other Types
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By End User: Hospital Pharmacies, Retail Pharmacies, Other End-Users Subsegments: 1) By Alpha Blocker: Tamsulosin, Alfuzosin, Doxazosin, Terazosin, Silodosin
2) By 5-alpha Reductase Inhibitor: Finasteride, Dutasteride
3) By Phosphodiesterase-5 Inhibitor: Tadalafil, Sildenafil
4) By Other Types: Anticholinergics, Herbal Supplements (Saw Palmetto), Combination Therapy Drugs (Alpha Blocker + 5-alpha Reductase Inhibitor)
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Allergan Inc., Astellas Pharma Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Sanofi S.A., Nymox Pharmaceutical Corporation, Æterna Zentaris Inc., Pfizer Inc., IntelGenx Technologies Corp., Ipsen S.A., Novartis International AG, Antibe Therapeutics Inc., Bausch Health Companies Inc., Bayer AG, Quest PharmaTech Inc., Bristol-Myers Squibb Company, Endo Pharmaceuticals Inc., Kaken Pharmaceutical Co. Ltd., Impax Laboratories Inc., GemVax & KAEL Inc., Merck & Co. Inc., Kissei Pharmaceutical Co. Ltd., Abbott Laboratories, Allium Medical Solutions Ltd., Asahi Kasei Corporation, Asclepion Laser Technologies GmbH, Boston Scientific Corporation, Biolitec AG, Coloplast A/S, Eli Lilly and Company, Endo International plc, IPG Photonics Corporation, KARL STORZ SE & Co. KG, LISA Laser Products AG, Medifocus Inc., Olympus Corporation, Pharex Health Corporation, PNN Medical A/S, Quanta S.p.A.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

2. Drugs For Benign Prostatic hypertrophy Market Characteristics

3. Drugs For Benign Prostatic hypertrophy Market Trends And Strategies

4. Drugs For Benign Prostatic hypertrophy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Drugs For Benign Prostatic hypertrophy Growth Analysis And Strategic Analysis Framework

5.1. Global Drugs For Benign Prostatic hypertrophy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Drugs For Benign Prostatic hypertrophy Market Growth Rate Analysis

5.4. Global Drugs For Benign Prostatic hypertrophy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Drugs For Benign Prostatic hypertrophy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Drugs For Benign Prostatic hypertrophy Total Addressable Market (TAM)

6. Drugs For Benign Prostatic hypertrophy Market Segmentation

6.1. Global Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Alpha Blocker

5-alpha Reductase Inhibitor

Phosphodiesterase-5 Inhibitor

Other Types

6.2. Global Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

6.3. Global Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacies

Retail Pharmacies

Other End-Users

6.4. Global Drugs For Benign Prostatic hypertrophy Market, Sub-Segmentation Of Alpha Blocker, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Tamsulosin

Alfuzosin

Doxazosin

Terazosin

Silodosin

6.5. Global Drugs For Benign Prostatic hypertrophy Market, Sub-Segmentation Of 5-alpha Reductase Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Finasteride

Dutasteride

6.6. Global Drugs For Benign Prostatic hypertrophy Market, Sub-Segmentation Of Phosphodiesterase-5 Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Tadalafil

Sildenafil

6.7. Global Drugs For Benign Prostatic hypertrophy Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Anticholinergics

Herbal Supplements (Saw Palmetto)

Combination Therapy Drugs (Alpha Blocker + 5-alpha Reductase Inhibitor)

7. Drugs For Benign Prostatic hypertrophy Market Regional And Country Analysis

7.1. Global Drugs For Benign Prostatic hypertrophy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Drugs For Benign Prostatic hypertrophy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Drugs For Benign Prostatic hypertrophy Market

8.1. Asia-Pacific Drugs For Benign Prostatic hypertrophy Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Drugs For Benign Prostatic hypertrophy Market

9.1. China Drugs For Benign Prostatic hypertrophy Market Overview

9.2. China Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Drugs For Benign Prostatic hypertrophy Market

10.1. India Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Drugs For Benign Prostatic hypertrophy Market

11.1. Japan Drugs For Benign Prostatic hypertrophy Market Overview

11.2. Japan Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Drugs For Benign Prostatic hypertrophy Market

12.1. Australia Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Drugs For Benign Prostatic hypertrophy Market

13.1. Indonesia Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Drugs For Benign Prostatic hypertrophy Market

14.1. South Korea Drugs For Benign Prostatic hypertrophy Market Overview

14.2. South Korea Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Drugs For Benign Prostatic hypertrophy Market

15.1. Western Europe Drugs For Benign Prostatic hypertrophy Market Overview

15.2. Western Europe Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Drugs For Benign Prostatic hypertrophy Market

16.1. UK Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Drugs For Benign Prostatic hypertrophy Market

17.1. Germany Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Drugs For Benign Prostatic hypertrophy Market

18.1. France Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Drugs For Benign Prostatic hypertrophy Market

19.1. Italy Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Drugs For Benign Prostatic hypertrophy Market

20.1. Spain Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Drugs For Benign Prostatic hypertrophy Market

21.1. Eastern Europe Drugs For Benign Prostatic hypertrophy Market Overview

21.2. Eastern Europe Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Drugs For Benign Prostatic hypertrophy Market

22.1. Russia Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Drugs For Benign Prostatic hypertrophy Market

23.1. North America Drugs For Benign Prostatic hypertrophy Market Overview

23.2. North America Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Drugs For Benign Prostatic hypertrophy Market

24.1. USA Drugs For Benign Prostatic hypertrophy Market Overview

24.2. USA Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Drugs For Benign Prostatic hypertrophy Market

25.1. Canada Drugs For Benign Prostatic hypertrophy Market Overview

25.2. Canada Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Drugs For Benign Prostatic hypertrophy Market

26.1. South America Drugs For Benign Prostatic hypertrophy Market Overview

26.2. South America Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Drugs For Benign Prostatic hypertrophy Market

27.1. Brazil Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Drugs For Benign Prostatic hypertrophy Market

28.1. Middle East Drugs For Benign Prostatic hypertrophy Market Overview

28.2. Middle East Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Drugs For Benign Prostatic hypertrophy Market

29.1. Africa Drugs For Benign Prostatic hypertrophy Market Overview

29.2. Africa Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Drugs For Benign Prostatic hypertrophy Market Competitive Landscape And Company Profiles

30.1. Drugs For Benign Prostatic hypertrophy Market Competitive Landscape

30.2. Drugs For Benign Prostatic hypertrophy Market Company Profiles

30.2.1. Allergan Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis

30.2.4. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Teva Pharmaceutical Industries Limited Overview, Products and Services, Strategy and Financial Analysis

31. Drugs For Benign Prostatic hypertrophy Market Other Major And Innovative Companies

31.1. Sanofi S.A.

31.2. Nymox Pharmaceutical Corporation

31.3. Æterna Zentaris Inc.

31.4. Pfizer Inc.

31.5. IntelGenx Technologies Corp.

31.6. Ipsen S.A.

31.7. Novartis International AG

31.8. Antibe Therapeutics Inc.

31.9. Bausch Health Companies Inc.

31.10. Bayer AG

31.11. Quest PharmaTech Inc.

31.12. Bristol-Myers Squibb Company

31.13. Endo Pharmaceuticals Inc.

31.14. Kaken Pharmaceutical Co. Ltd.

31.15. Impax Laboratories Inc.

32. Global Drugs For Benign Prostatic hypertrophy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Drugs For Benign Prostatic hypertrophy Market

34. Recent Developments In The Drugs For Benign Prostatic hypertrophy Market

35. Drugs For Benign Prostatic hypertrophy Market High Potential Countries, Segments and Strategies

35.1 Drugs For Benign Prostatic hypertrophy Market In 2029 - Countries Offering Most New Opportunities

35.2 Drugs For Benign Prostatic hypertrophy Market In 2029 - Segments Offering Most New Opportunities

35.3 Drugs For Benign Prostatic hypertrophy Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Drugs For Benign Prostatic hypertrophy Market, Sub-Segmentation Of Alpha Blocker, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Drugs For Benign Prostatic hypertrophy Market, Sub-Segmentation Of 5-alpha Reductase Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Drugs For Benign Prostatic hypertrophy Market, Sub-Segmentation Of Phosphodiesterase-5 Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Drugs For Benign Prostatic hypertrophy Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Drugs For Benign Prostatic hypertrophy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Drugs For Benign Prostatic hypertrophy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Asia-Pacific, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Asia-Pacific, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Asia-Pacific, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: China, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: China, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: China, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: India, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: India, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: India, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: Japan, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: Japan, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Japan, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Australia, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Australia, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Australia, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Indonesia, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Indonesia, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Indonesia, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: South Korea, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: South Korea, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: South Korea, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: Western Europe, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: Western Europe, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: Western Europe, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: UK, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: UK, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: UK, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: Germany, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: Germany, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: Germany, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: France, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: France, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: France, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: Italy, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Italy, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Italy, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Spain, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Spain, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Spain, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Eastern Europe, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Eastern Europe, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Eastern Europe, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Russia, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Russia, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Russia, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: North America, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: North America, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: North America, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: USA, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: USA, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: USA, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: Canada, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: Canada, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: Canada, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: South America, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: South America, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: South America, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: Brazil, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Brazil, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Brazil, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Middle East, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Middle East, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Middle East, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Africa, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Africa, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Africa, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Allergan Inc. Financial Performance
  • Table 79: Astellas Pharma Inc. Financial Performance
  • Table 80: Boehringer Ingelheim International GmbH Financial Performance
  • Table 81: GlaxoSmithKline plc Financial Performance
  • Table 82: Teva Pharmaceutical Industries Limited Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Drugs For Benign Prostatic hypertrophy Market, Sub-Segmentation Of Alpha Blocker, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Drugs For Benign Prostatic hypertrophy Market, Sub-Segmentation Of 5-alpha Reductase Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Drugs For Benign Prostatic hypertrophy Market, Sub-Segmentation Of Phosphodiesterase-5 Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Drugs For Benign Prostatic hypertrophy Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Drugs For Benign Prostatic hypertrophy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Drugs For Benign Prostatic hypertrophy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Asia-Pacific, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Asia-Pacific, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Asia-Pacific, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: China, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: China, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: China, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: India, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: India, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: India, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: Japan, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: Japan, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Japan, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Australia, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Australia, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Australia, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Indonesia, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Indonesia, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Indonesia, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: South Korea, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: South Korea, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: South Korea, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: Western Europe, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: Western Europe, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: Western Europe, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: UK, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: UK, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: UK, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: Germany, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: Germany, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: Germany, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: France, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: France, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: France, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: Italy, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Italy, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Italy, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Spain, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Spain, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Spain, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Eastern Europe, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Eastern Europe, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Eastern Europe, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Russia, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Russia, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Russia, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: North America, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: North America, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: North America, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: USA, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: USA, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: USA, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: Canada, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: Canada, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: Canada, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: South America, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: South America, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: South America, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: Brazil, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Brazil, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Brazil, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Middle East, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Middle East, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Middle East, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Africa, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Africa, Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Africa, Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Allergan Inc. Financial Performance
  • Figure 79: Astellas Pharma Inc. Financial Performance
  • Figure 80: Boehringer Ingelheim International GmbH Financial Performance
  • Figure 81: GlaxoSmithKline plc Financial Performance
  • Figure 82: Teva Pharmaceutical Industries Limited Financial Performance

Strategic Growth Drivers Shaping the Nutraceutical Excipients Market Outlook 2025- 2034:The Role Of Health And Wellness In Driving Growth In The Nutraceutical Excipients Market

Read More About Strategic Growth Drivers Shaping the Nutraceutical Excipients Market Outlook 2025- 2034:The Role Of Health And Wellness In Driving Growth In The Nutraceutical Excipients Market

Emerging Growth Drivers in the Opioids Market Landscape: Growing Surgical Procedures Fueling Demand In The Opioids Market

Read More About Emerging Growth Drivers in the Opioids Market Landscape: Growing Surgical Procedures Fueling Demand In The Opioids Market

Osimertinib Drugs Market Outlook 2025–2034: Identifying Growth Drivers, Technology Trends, and Policy Impact

Read More About Osimertinib Drugs Market Outlook 2025–2034: Identifying Growth Drivers, Technology Trends, and Policy Impact

Otic Drugs Market Insights: In-Depth Look at Growth Trends, Market Size, and Opportunities for 2025-2034

Read More About Otic Drugs Market Insights: In-Depth Look at Growth Trends, Market Size, and Opportunities for 2025-2034

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

Read More About A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

Read More About A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

Uncover TBRC’s strategic outlook on technological trends, regulatory factors, and market growth in transdermal drug delivery systems.

Read More About Uncover TBRC’s strategic outlook on technological trends, regulatory factors, and market growth in transdermal drug delivery systems.

Explore forecast data, therapeutic advancements, and pipeline progress in TBRC’s Tuberous Sclerosis Drug Market report.

Read More About Explore forecast data, therapeutic advancements, and pipeline progress in TBRC’s Tuberous Sclerosis Drug Market report.

Genito-Urinary Drugs Global Market Report 2022 – By Type (Hormonal Contraceptives, Drugs For Benign Prostatic hypertrophy, Drugs For Infertility, Drugs For Erectile Dysfunction, Drugs For Urinary Incontinence And Overact...

View Report

Dermatology Drugs Global Market Report 2022 – By Type (Acne Drugs, Dermatitis, Psoriasis, Other Drugs for Dermatology Diseases), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others), By R...

View Report

Cardiovascular Drugs Global Market Report 2022 – By Type (Anti-Hypertensive Drugs, Hypolipidemics, Anti Thrombotics, Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrhythmic And Anti-Anginal Dru...

View Report

Musculoskeletal Disorders Drugs Global Market Report 2022 – By Type (Drugs For Rheumatoid Arthritis, Muscle Relaxants, Other Musculoskeletal Disorders Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmaci...

View Report

Drugs For Erectile Dysfunction Global Market Report 2025 – By Drugs (Sildenafil Citrate, Mirodenafil, Vardenafil), By Mode of Administration (Oral, Topical, Injections), By End users (Hospital Pharmacies, Retail Pharmaci...

View Report

Drugs for Immunotherapy Global Market Report 2025 – By Type (Monoclonal Antibodies, Interferons, Interleukins, Vaccines, Checkpoint Inhibitors, Other Types), By Therapy Area (Cancer, Autoimmune & Inflammatory Diseases, I...

View Report

Drugs For Benign Prostatic hypertrophy Global Market Report 2025 – By Type (Alpha Blocker, 5-alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitor, Other Types), By Distribution Channel (Hospital Pharmacies, Retail Ph...

View Report

Diuretics Global Market Report 2025 – By Type (Osmotic Diuretics, Carbonic Anhydrase Inhibitors, Loop Diuretics, Thiazides & Thiazide-Like Diuretics, Aldosterone Antagonists), By Distribution (Hospital Pharmacies, Indepe...

View Report

Frequently Asked Questions

The drug benign prostatic hypertrophy refers to benign prostatic hypertrophy drugs that are used to treat enlarged prostate glands by relaxing bladder neck muscles and muscle fibers in the prostate, making urination easier. Benign Prostatic Hypertrophy is commonly seen in men older than 50. For further insights on this market, request a sample here

The market major growth driver - Rising Geriatric Population Drives Growth Of Benign Prostatic Hypertrophy Drugs Market. For further insights on this market, request a sample here

The drugs for benign prostatic hypertrophy market size has grown strongly in recent years. It will grow from $4.31 billion in 2024 to $4.55 billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to aging population, increased awareness, advancements in drug therapies, healthcare access. The drugs for benign prostatic hypertrophy market size is expected to see steady growth in the next few years. It will grow to " $5.52 billion in 2029 at a compound annual growth rate (CAGR) of 5.0%. The growth in the forecast period can be attributed to emerging markets, new drug developments, increasing awareness and education, regulatory approvals. Major trends in the forecast period include minimally invasive treatments, personalized medicine, combination therapies, patient-centered care, telemedicine and digital health, research and development. For further insights on this market, request a sample here

The drugs for benign prostatic hypertrophy market covered in this report is segmented –
1) By Type: Alpha Blocker, 5-alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitor, Other Types
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By End User: Hospital Pharmacies, Retail Pharmacies, Other End-Users Subsegments:
1) By Alpha Blocker: Tamsulosin, Alfuzosin, Doxazosin, Terazosin, Silodosin
2) By 5-alpha Reductase Inhibitor: Finasteride, Dutasteride
3) By Phosphodiesterase-5 Inhibitor: Tadalafil, Sildenafil
4) By Other Types: Anticholinergics, Herbal Supplements (Saw Palmetto), Combination Therapy Drugs (Alpha Blocker + 5-alpha Reductase Inhibitor) For further insights on this market, request a sample here

North America was the largest region in the drugs for benign prostatic hypertrophy market in 2024. Middle East is expected to be the fastest-growing region in the drugs for benign prostatic hypertrophy market. The regions covered in the drugs for benign prostatic hypertrophy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa For further insights on this market, request a sample here.

Major companies operating in the drugs for benign prostatic hypertrophy market include Allergan Inc., Astellas Pharma Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Sanofi S.A., Nymox Pharmaceutical Corporation, Æterna Zentaris Inc., Pfizer Inc., IntelGenx Technologies Corp., Ipsen S.A., Novartis International AG, Antibe Therapeutics Inc., Bausch Health Companies Inc., Bayer AG, Quest PharmaTech Inc., Bristol-Myers Squibb Company, Endo Pharmaceuticals Inc., Kaken Pharmaceutical Co. Ltd., Impax Laboratories Inc., GemVax & KAEL Inc., Merck & Co. Inc., Kissei Pharmaceutical Co. Ltd., Abbott Laboratories, Allium Medical Solutions Ltd., Asahi Kasei Corporation, Asclepion Laser Technologies GmbH, Boston Scientific Corporation, Biolitec AG, Coloplast A/S, Eli Lilly and Company, Endo International plc, IPG Photonics Corporation, KARL STORZ SE & Co. KG, LISA Laser Products AG, Medifocus Inc., Olympus Corporation, Pharex Health Corporation, PNN Medical A/S, Quanta S.p.A.. For further insights on this market, request a sample here.

Major trends in this market include Innovations In Benign Prostatic Hypertrophy Treatment. For further insights on this market, request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us
Global Drugs For Benign Prostatic hypertrophy Market Report 2025

Wait, we have a special offer for you! ✋

Get your exclusive 20% discount only on the Global Market Reports now using the code ONLINE20*

YES, get the discount! No, I'd pay the full price

*Copy paste the discount code in the cart

Back to top